Posted by Michael Wonder on 27 Nov 2021
Shingrix approved in Canada for adults at increased risk of shingles due to immunodeficiency or immunosuppression
25 November 2021 - GlaxoSmithKline today announced that Shingrix (Zoster Vaccine Recombinant, Adjuvanted) has been approved in Canada for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or who will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy.
Immunocompromised individuals are at greater risk of shingles and associated complications than immunocompetent individuals. This indication expansion marks an important step towards increasing access to a shingles vaccine for Canadians with diverse risk factors that put them at increased risk of shingles.
